No black box warning on record for Ogivri

As of the latest FDA labeling reviewed, Ogivri (TRASTUZUMAB-DKST) does not carry a black box warning. Standard warnings and precautions still apply — see the full Ogivri medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Exacerbation of Chemotherapy-Induced Neutropenia. ( 5.5 , 6.1 ) 5.1 Cardiomyopathy Trastuzumab products can cause left ventricular cardiac dysfunction, arrhythmias, hypertension, disabling cardiac failure, cardiomyopathy, and cardiac death [see Boxed Warning: Cardiomyopathy ] . Trastuzumab products can also cause asymptomatic decline in left ventricular ejection fracti

No black box warning on record for Ogivri

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Exacerbation of Chemotherapy-Induced Neutropenia. ( 5.5 , 6.1 ) 5.1 Cardiomyopathy Trastuzumab products can cause left ventricular cardiac dysfunction, arrhythmias, hypertension, disabling cardiac failure, cardiomyopathy, and cardiac death [see Boxed Warning: Cardiomyopathy ] . Trastuzumab products can also cause asymptomatic decline in left ventricular ejection fracti

Ogivri Black Box Warning

No black box warning on record for Ogivri

Other warnings & precautions

Ogivri Black Box Warning

No black box warning on record for Ogivri

Other warnings & precautions